Sui stablecoin volume hits $65B after fee cut
Sui has processed nearly $65 billion in stablecoin transactions since June 10 after introducing protocol-level fee-free transfers, according to blockchain security firm CertiK.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Sui has processed nearly $65 billion in stablecoin transactions since June 10 after introducing protocol-level fee-free transfers, according to blockchain security firm CertiK.
Sigma Healthcare (ASX:SIG) has walked away from preliminary discussions to acquire UK health and beauty retailer Boots.
Anthropic has suspended worldwide access to its Mythos and Fable 5 artificial intelligence models after the Trump administration imposed export controls amid concerns that a China-linked group may have gained access to the company’s most advanced cybersecurity technology.
The takeover battle for outdoor advertising giant oOh!media (ASX:OML) intensifies as revised private equity bids converge at up to $1.60 per share.
The Digital Asset Market Clarity Act has been placed on the US Senate Legislative Calendar, with lawmakers racing to secure a floor vote before the 119th Congress concludes and the legislative process potentially resets.
ASX (ASX:ASX) faces a $20.5 million fine after admitting to misleading the market over its failed CHESS upgrade project.
The CLARITY Act is unlikely to reach final passage by 4 July, delaying White House hopes of signing a major US crypto bill on America’s 250th birthday.
Kalshi, Crypto.com, Polymarket and other prediction market platforms have jointly filed a lawsuit in Kentucky state court to block a new 14.25% tax on transaction fees.
Disc Medicine (NASDAQ:IRON) disclosed positive, updated clinical data across its core hematology pipeline during the 2026 European Hematology Association (EHA) Annual Meeting in Stockholm, Sweden.
Cogent Biosciences (NASDAQ:COGT) announced detailed clinical results from its registration-directed APEX trial evaluating its investigational precision therapy, bezuclastinib, in patients with advanced systemic mastocytosis (AdvSM).